OraSure Technologies (NASDAQ:OSUR – Get Free Report) and Cresco Labs (OTCMKTS:CRLBF – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.
Institutional and Insider Ownership
93.5% of OraSure Technologies shares are owned by institutional investors. Comparatively, 0.1% of Cresco Labs shares are owned by institutional investors. 4.7% of OraSure Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for OraSure Technologies and Cresco Labs, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OraSure Technologies | 1 | 1 | 0 | 0 | 1.50 |
| Cresco Labs | 0 | 1 | 0 | 1 | 3.00 |
Profitability
This table compares OraSure Technologies and Cresco Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OraSure Technologies | -66.42% | -18.57% | -15.71% |
| Cresco Labs | -20.90% | -17.98% | -4.29% |
Valuation & Earnings
This table compares OraSure Technologies and Cresco Labs”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OraSure Technologies | $115.02 million | 2.62 | -$68.73 million | ($1.04) | -4.21 |
| Cresco Labs | $655.85 million | 0.62 | -$135.41 million | ($0.39) | -2.08 |
OraSure Technologies has higher earnings, but lower revenue than Cresco Labs. OraSure Technologies is trading at a lower price-to-earnings ratio than Cresco Labs, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
OraSure Technologies has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. Comparatively, Cresco Labs has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500.
Summary
Cresco Labs beats OraSure Technologies on 9 of the 14 factors compared between the two stocks.
About OraSure Technologies
OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.
About Cresco Labs
Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections and fruit-forward gummies under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company was incorporated in 1990 and is headquartered in Chicago, Illinois.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
